157 related articles for article (PubMed ID: 35217280)
1. Randomized trial of topical ascorbic acid in DMSO versus imiquimod for the treatment of basal cell carcinoma.
Burke B; Bailie JE
Biomed Pharmacother; 2022 Apr; 148():112710. PubMed ID: 35217280
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
4. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature.
Drehs MM; Cook-Bolden F; Tanzi EL; Weinberg JM
Dermatol Surg; 2002 May; 28(5):427-9. PubMed ID: 12030878
[TBL] [Abstract][Full Text] [Related]
6. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
7. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Love WE; Bernhard JD; Bordeaux JS
Arch Dermatol; 2009 Dec; 145(12):1431-8. PubMed ID: 20026854
[TBL] [Abstract][Full Text] [Related]
8. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
Lecluse LL; Spuls PI
Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
11. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
13. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
Ozolins M; Williams HC; Armstrong SJ; Bath-Hextall FJ
Trials; 2010 Apr; 11():42. PubMed ID: 20409337
[TBL] [Abstract][Full Text] [Related]
14. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial.
Williams HC; Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PSJ;
J Invest Dermatol; 2017 Mar; 137(3):614-619. PubMed ID: 27932240
[TBL] [Abstract][Full Text] [Related]
15. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report.
Micali G; De Pasquale R; Caltabiano R; Impallomeni R; Lacarrubba F
J Dermatolog Treat; 2002 Sep; 13(3):123-7. PubMed ID: 12227875
[TBL] [Abstract][Full Text] [Related]
16. The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions.
Cannon PS; O'Donnell B; Huilgol SC; Selva D
Br J Ophthalmol; 2011 Dec; 95(12):1682-5. PubMed ID: 20702431
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.
Prokosch V; Thanos S; Spaniol K; Stupp T
Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):121-5. PubMed ID: 20886224
[TBL] [Abstract][Full Text] [Related]
18. A preliminary study of imiquimod treatment in variants of basal cell carcinoma.
McCutcheon B; White K; Kotwall C; Germolic D; Rebolloso Y; Hamann MS; Stiles A
Am Surg; 2005 Aug; 71(8):662-5. PubMed ID: 16217949
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
20. A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma.
Eigentler TK; Kamin A; Weide BM; Breuninger H; Caroli UM; Möhrle M; Radny P; Garbe C
J Am Acad Dermatol; 2007 Oct; 57(4):616-21. PubMed ID: 17610993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
